在神经退行性疾病中探索孤儿GPCRs
Devrim Öz-Arslan1,2, Melis Yavuz2,3, Beki Kan1,2
1Department of Biophysics, Acibadem MAA University, School of Medicine, Istanbul, Türkiye.
Frontiers in pharmacology
|June 19, 2024
概括
孤儿受体,特别是A类孤儿,在治疗神经退行性疾病,如阿尔茨海默氏症和帕金森氏症方面表现有前途. 针对这些受体为治疗选择有限的疾病提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 神经退行性疾病是一个日益增长的全球健康挑战,有效治疗方法有限.
- 了解分子机制对于开发新疗法至关重要.
- 孤儿受体缺乏已知的配体,正在成为有希望的药物标.
研究的目的:
- 审查A类孤儿G蛋白结合受体 (GPCRs) 在神经退行性疾病中的作用.
- 要突出它们在突触传播,神经元存活和神经炎症中的参与.
- 讨论针对这些受体的治疗策略.
主要方法:
- 文献综述,重点关注神经退行性疾病中孤儿GPCRs.
- 对它们的细胞功能和治疗潜力的分析.
- 检查最近的药物发现和临床前发现.
主要成果:
- 甲类孤儿GPCR在阿尔茨海默病,帕金森病,亨廷顿病和多发性硬化症中起着重要的作用.
- 这些受体调节关键的神经元过程,包括突触功能和炎症.
- 最近的研究表明,有潜力针对它们进行治疗.
结论:
- 孤儿GPCRs代表了新型神经退行性疾病治疗的有前途的目标类.
- 需要进一步的研究和药物开发,才能充分利用它们的治疗潜力.
- 解决孤儿受体研究中的挑战是未来进步的关键.
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...


